



March 2nd, 2016, het Pand
<http://mellfire.ugent.be/public/oncopoint/>

- 8.45-9.00 **Opening**
- 09.00-09.45 **Keynote speaker**
Patient-Derived Tumor Xenograft Models: an emerging way to personalized medicine in translational cancer research
Frederic Amant (KULeuven)
- 09.45-10.05 **Selected abstract presentations**
RIPK3-dependent necroptosis is immunogenic – a new target in anti-cancer therapy?
Tania Løve Aaes
- 10.05-10.25 Decoding cancer transcriptomes using public RNA sequencing data
Celine Everaert
- 10.25-10.35 **Company presentation (Perkin Elmer)**
- 10.35-10.50 **Short abstract presentations 1**
- 10.50-11.20 **Coffee break**
- 11.20-12.05 **Keynote speaker**
Intravital imaging of cancer invasion, metastasis and resistance to therapy
Peter Friedl (Radboudumc, Nijmegen/MD Anderson Cancer Center, Houston)
- 12.05-12.25 **Selected abstract presentations**
Radiotherapy-induced damage to cancer-associated fibroblasts promotes colorectal cancer progression through IGF-1/AKT signalling
Joke Tommelein
- 12.25-12.45 AcTakine strategy for safe systemic application of cytokines in cancer immunotherapy, proof of principle using a type I IFN-based AcTaferon
Anje Cauwels
- 12.45-13.45 **Lunch**

- Selected abstract presentations**
- 13.45-14.05 Targeting BET family proteins improves the efficacy of ABT-199 in T-cell acute lymphoblastic leukemia
Sofie Peirs
- 14.05-14.25 Xenogeneic vascular endothelial growth factor-2 vaccination in tumor bearing mice
Niek Sanders
- 14.25-14.35 **Company presentation (AstraZeneca)**
Is Immuno-oncology therapy the Holy Grail for cancer treatment?
- 14.35-15.05 **Short abstract presentations 2**
- 15.05-15.40 **Coffee break**
- Selected abstract presentation**
- 15.40-16.00 Exploring the role of the PHF6 tumor suppressor gene in DNA repair in T-cell acute lymphoblastic leukemia
Renate De Smedt
- 16.00-16.10 **Company presentation (Biocartis)**
- Selected abstract presentation**
- 16.10-16.30 Thorough Second hit analysis in BRCA1/2 associated breast cancer
Mattias Van Heetvelde
- 16.30-16.50 Furan-based crosslinking in situ: seizing ligand-receptor complexes in the act
Annemieke Madder
- 16.50-17.10 Nanobody footprinting of cortactin in cancer cell invasion
Laurence Bertier
- 17.10-17.40 **Short abstract presentation 3**
- 17.40-18.00 **Final conclusions, announcements of awards**